Hoopes Vision in Draper, Utah, has begun using Rayner’s Galaxy intraocular lens, a surgically implanted artificial lens whose spiral optical design was developed with AI assistance. The clinic’s October 26, 2026, announcement scheduled three patients for implantation on October 27 and described them as Utah’s first recipients.
Fox 13 subsequently reported that ophthalmologist Dr. Benjamin Buckner had begun using the lens. That establishes a local deployment, although the report does not confirm completion of all three scheduled procedures or identify the exact lens model each patient received.
Galaxy aims to provide useful vision at near, intermediate and far distances while limiting glare and halos, potentially reducing dependence on glasses. Those benefits are claims from the clinic and manufacturer representatives in the rollout coverage. Neither account supplies independently assessed clinical outcomes for the Utah recipients.
Published research does provide evidence beyond the announcement. The important distinction is between an implant reaching patients, researchers measuring its performance, and a controlled comparison showing that it improves on another lens. The available sources address those questions differently.
What Was Implanted in Utah
Galaxy is an intraocular lens, or IOL: a physical optical implant placed inside the eye. Its AI connection concerns development of the lens design, not an AI system operating inside the patient.
The FDA’s Summary of Safety and Effectiveness Data identifies two approved versions:
- RayOne Galaxy, model RAO605G, for patients with less than 1.00 diopter of pre-existing corneal astigmatism.
- RayOne Galaxy Toric, model RAO615X, which also addresses corneal astigmatism within a specified range.
Both are intended for adults whose cataractous natural lens has been removed. The implant sits in the capsular bag, the structure that previously held the natural lens. A preloaded injection system folds and assists with inserting it. The optical portion measures 6 millimeters across; the overall implant diameter is approximately 12.5 millimeters.
Fox 13 identifies Corey Hansen, a collision-center owner, as one of Buckner’s first Galaxy patients. Hansen described declining eyesight and hoped the procedure would help him return to activities that had become difficult. Those statements explain his reasons for choosing surgery; they are expectations, not postoperative measurements.
Hoopes’ announcement describes a broader goal of reducing glasses dependence. Whether an individual achieves that depends on the visual result and their needs, and the clinic explicitly says outcomes vary.
How AI Helped Shape the Spiral Optics
Rayner regional sales director Brian Bonjour told Fox 13 that developers used an AI model to help create a lens around desired optical qualities, producing the spiral design. The report offers a high-level account, without details about the model architecture, training data or optimization process.
The physical mechanism is better documented. According to the FDA, Galaxy has a refractive spiral front surface and an aspheric back surface. The toric version has a back surface shaped to correct astigmatism. Its spiral region provides additional focusing powers for intermediate and near vision.
A conventional monofocal IOL generally prioritizes one viewing distance. Presbyopia-correcting lenses expand that range, with optical tradeoffs. The 2025 Journal of Refractive Surgery paper explains that traditional diffractive trifocal designs split light among focal points, which can contribute to reduced contrast and unwanted light effects, especially in low-light conditions.
Galaxy instead uses non-diffractive, refractive spiral tracks. Its goal is a smooth range of useful vision with fewer distracting optical effects.
The FDA still classifies Galaxy as a multifocal, trifocal IOL. That terminology is compatible with researchers describing a continuous range: one describes its optical classification, while the other describes measured performance across changing focus.
My view is that the spiral’s measured behavior matters more than the AI label. AI assistance is an interesting development method, but patients experience image quality, reading ability and night-driving comfort, not the design process.
What the Published Studies Actually Show
Two published studies provide context for the Utah rollout. Their designs matter as much as their favorable results.
| Published evidence | What researchers evaluated | Reported findings | Important limit |
|---|---|---|---|
| Journal of Refractive Surgery, November 1, 2025 | Preclinical vision simulation comparing Galaxy with Rayner’s diffractive RayOne Trifocal, followed by clinical outcomes from 10 sites after bilateral Galaxy implantation | Comparable simulated focus range with less halo/glare; clinical binocular acuity of 20/32 or better across the reported defocus range at three months | The direct lens comparison used simulation; it was separate from the postoperative clinical assessment |
| Graefe’s Archive for Clinical and Experimental Ophthalmology, September 19, 2026 | Prospective observational study of 98 eyes in 49 patients receiving Galaxy in both eyes, followed for three months | Functional vision across a continuous defocus range, improved patient-reported visual function, and reduced halo/glare between months one and three | No comparison group receiving another lens |
The 2025 paper reports binocular visual acuity of 20/32 or better from +1.00 to −2.80 diopters on its defocus curve. A defocus curve measures how vision holds up as added lens power changes the focusing demand. Here, it supports the authors’ account of a broad useful range.
The same paper reports that halo and glare symptoms were generally minor in more than 95% of patients, with no severe cases reported. Its simulation component found significantly less halo/glare with Galaxy than with the tested diffractive trifocal lens.
That separation is consequential. A simulated comparison offers evidence about optical performance under its test conditions. It is different from assigning surgical patients to competing implants and comparing their daily experiences afterward.
The September 2026 study followed patients aged 43 to 79 after bilateral cataract surgery. It reported functional binocular vision, defined as 0.2 logMAR or better, across +1.00 to −2.50 diopters. A value of 0.2 logMAR corresponds to approximately 20/32 vision; lower logMAR values indicate better acuity.
Researchers also measured intermediate vision at 66 centimeters and near vision at 40 centimeters with distance correction in place. That condition matters: distance-corrected near acuity measures what the optics can deliver after correcting residual distance error. It is not the same endpoint as reading unaided.
Frequently Asked Questions
3 questions
1Is AI Running Inside the Galaxy Lens?
The documented AI role was in developing the spiral optical design. Galaxy is a physical lens implant; the sources do not describe an onboard AI system.
